Cellular and novel immunotherapies currently available in LATAM countries
| Therapy . | Countries with regulatory approval . | Label of approval/indication . | Countries with availability in clinical trials . |
|---|---|---|---|
| Tisagenlecleucel∗ (Kymriah) | Brazil | RR B ALL CD19+ RR DLBCNHL | Chile, Colombia, Mexico, and Uruguay |
| Axicabtagene ciloleucel∗ (Yescarta) | Brazil | RR DLBCNHL | |
| Ciltacabtagene autoleucel∗ (Carvykti) | Brazil | MM relapsed to 3 or more lines of therapies | Argentina |
| Inotuzumab ozogamicin† (Besponsa) | Argentina, Brazil, Chile, and Mexico | RR B ALL CD22+ | |
| Belantamab mafodotin† (Blenrep) | None | MM relapsed to 3 or more lines of therapies | Argentina and Brazil |
| Polatuzumab vedotin† (Polivy) | Argentina, Brazil, Colombia, and Mexico | DLBCNHL (in combination with immunochemotherapy) | |
| Blinatumomab‡ (Blincyto) | Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Paraguay | RR ALL CD19+ | |
| Teclistamab‡ (Tecvayli) | Argentina, Brazil, Costa Rica, Guatemala, Mexico, Panama, Peru, and Dominican Republic | MM relapsed to 3 or more lines of therapies | Argentina |
| Elranatamab‡ (Elrexfio) | Brazil | MM relapsed to 3 or more lines of therapies | Argentina (compassionate use) and Mexico |
| Talquetamab‡ (Talvey) | Brazil and Mexico | MM relapsed to 3 or more lines of therapies | Argentina and Mexico |
| Epcoritamab‡ (Epkinly) | Brazil, Mexico, and Argentina | RR DLBCNHL to 2 or more lines of therapies | Argentina, Colombia, and Mexico |
| Therapy . | Countries with regulatory approval . | Label of approval/indication . | Countries with availability in clinical trials . |
|---|---|---|---|
| Tisagenlecleucel∗ (Kymriah) | Brazil | RR B ALL CD19+ RR DLBCNHL | Chile, Colombia, Mexico, and Uruguay |
| Axicabtagene ciloleucel∗ (Yescarta) | Brazil | RR DLBCNHL | |
| Ciltacabtagene autoleucel∗ (Carvykti) | Brazil | MM relapsed to 3 or more lines of therapies | Argentina |
| Inotuzumab ozogamicin† (Besponsa) | Argentina, Brazil, Chile, and Mexico | RR B ALL CD22+ | |
| Belantamab mafodotin† (Blenrep) | None | MM relapsed to 3 or more lines of therapies | Argentina and Brazil |
| Polatuzumab vedotin† (Polivy) | Argentina, Brazil, Colombia, and Mexico | DLBCNHL (in combination with immunochemotherapy) | |
| Blinatumomab‡ (Blincyto) | Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Paraguay | RR ALL CD19+ | |
| Teclistamab‡ (Tecvayli) | Argentina, Brazil, Costa Rica, Guatemala, Mexico, Panama, Peru, and Dominican Republic | MM relapsed to 3 or more lines of therapies | Argentina |
| Elranatamab‡ (Elrexfio) | Brazil | MM relapsed to 3 or more lines of therapies | Argentina (compassionate use) and Mexico |
| Talquetamab‡ (Talvey) | Brazil and Mexico | MM relapsed to 3 or more lines of therapies | Argentina and Mexico |
| Epcoritamab‡ (Epkinly) | Brazil, Mexico, and Argentina | RR DLBCNHL to 2 or more lines of therapies | Argentina, Colombia, and Mexico |
Belantamab mafodotin is no longer available in the United States and Europe.
RR B ALL, relapsed/refractory B-cell acute lymphoblastic leukemia; RR DLBCNHL, relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
CAR-Ts: tisagenlecleucel (anti-CD19), axicabtagene ciloleucel (anti-CD19), and ciltacabtagene autoleucel (anti-BCMA).
Antibody-drug conjugates: inotuzumab ozogamicin (anti-CD22 + ozogamicin), belantamab mafodotin (anti-BCMA + monomethyl auristatin F), and polatuzumab vedotin (anti-CD79b + monomethyl auristatin).
Bispecific antibodies: blinatumomab (anti-CD19 + anti-CD3), teclistamab (anti-BCMA + anti-CD3), elranatamab (anti-BCMA + anti-CD3), talquetamab (anti-GPRC5B + anti-CD3), and epcoritamab (anti-CD20 + anti-CD3).